Clinical Trial Update: Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and tolerability of V501 in Japanese males with anogenital HPV infection and condyloma acuminata; trial completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anogenital Human Papillomavirus Infection
• Condyloma Acuminata

Drugs mentioned

• V501 (HPV vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anogenital Human Papilloma Virus Infection, Condyloma Acuminata | Phase 3 | Status: COMPLETED | Results posted: 2018-08-31